breast cancer and glp 1 Study links GLP-1 drugs to lower diagnosis rates GLP-1 drugs cut breast cancer

P = 0.755) and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline (hazard ratio 0.73

Nighttime blood pressure is especially important because it predicts heart problems better than daytime readings

doi: 10.1007/s00592-023-02184-y

However, Novo Nordisk has recently developed monoclonal antibodies which, through targeting of the extracellular domain of GLP-1R, allow the detection of GLP-1R in human and rodent tissues with improved selectivity [[392], [393], [394]]

Wegovy works as a GLP-1 receptor agonist, meaning it mimics the action of glucagon-like peptide-1, a naturally occurring gut hormone

Pharmaceutical peptides have extensive safety monitoring and post-market surveillance